Drugs / LPX-TI641
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06982352 | Jun 2025 → Jan 2026 overdue | atopic eczema, psoriasis | LAPIX Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06628206 | Dec 2024 → Dec 2025 overdue | psoriatic arthritis | LAPIX Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05853835 | Oct 2023 → Aug 2024 | multiple sclerosis | LAPIX Therapeutics Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-12-10 | LAPIX Therapeutics Inc. | Results LAPIX Therapeutics Reports Positive Bioequivalence for Oral Capsule and New Safety Milestones in the LPX-TI641 Program lapix.com ↗
The new oral capsule advances into Phase Ib studies as GLP data establish a new NOAEL, expanding safety margins for LPX-TI641 development. |
| 2024-11-20 | LAPIX Therapeutics Inc. | Results LAPIX Therapeutics Announces Positive Topline Phase 1 Clinical Data Results with LPX-TI641 for the Treatment of Autoimmune Diseases lapix.com ↗
In healthy adults, LPX-TI641 was orally bioavailable and was safe and well tolerated up to the highest tested doses. |
| 2023-09-18 | LAPIX Therapeutics Inc. | Regulatory LAPIX Therapeutics Inc. Announces FDA Clearance of IND Application for its Treg-expanding TIM3/4 Agonist LPX-TI641 to Treat Multiple Sclerosis lapix.com ↗
LAPIX Therapeutics, Inc. (“LAPIX”), a biopharmaceutical company focused on developing novel, orally bioavailable immune system restoration therapies for autoimmune diseases, today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for its first-in-class, immune tolerance restoration small molecule, LPX-TI641, for the treatment of multiple sclerosis (MS). |
| 2023-05-17 | LAPIX Therapeutics Inc. | Regulatory LAPIX Therapeutics Inc. Announces the Issuance of U.S. Patent for LPX-TI641, Its First-in-Class, Orally Administered TIM3/4 Agonist for Treg Expansion to Treat Autoimmune Diseases lapix.com ↗
LAPIX Therapeutics, Inc. (“LAPIX”), a biopharma company focused on developing novel, orally bioavailable immune system restoration therapies for autoimmune diseases and oncology, today announced the U.S. Patent & Trademark Office issued its U.S. Patent No. 11,648,225, entitled “Compositions And Methods For Reducing Immune Intolerance And Treating Autoimmune Disorders.” |
All press releases naming this drug 8 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LPX-TI641 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06982352 ↗ |
| Action | Activate | “an orally bioavailable Tim family agonist (Tim-3 and Tim-4)” NCT05853835 ↗ |
| Modality | Small molecule | “a small molecule for immune tolerance restoration/induction” NCT05853835 ↗ |
| Route | Oral | “orally bioavailable” NCT05853835 ↗ |